Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics in Premature Birth Outcomes
NCT05710575Completed
- Sponsor
- University of Health Sciences Lahore
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, single-blind trial of lactobacillus reuteri in necrotizing enterocolitis (NEC) (2 arms), sponsored by University of Health Sciences Lahore. Primary endpoints: Incidence of Necrotizing Enterocolitis at 1 month and Incidence of Prolonged Hospital Stay at 1 month. Started Feb 2023; status: completed.
02
Drugs
lactobacillus reuteri
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT05710575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710575.